EssilorLuxottica Advances Pediatric Myopia Strategy With New Comfort Study on A.M.L. Lenses

Essilorluxottica (OTC) (ESLOY) announced an update on their ongoing clinical study.

Study Overview: Essilor International, part of EssilorLuxottica (OTC: ESLOY), is running a new clinical study titled “An Evaluation of Visual Comfort, Adaptation and Overall Satisfaction in Myopic Children Using A.M.L. Series of Lenses.” The goal is to see how well children with nearsightedness adapt to these new myopia control lenses and how satisfied they feel while wearing them. This work matters because real‑world comfort and ease of use are key for wider adoption of pediatric myopia control solutions, a fast‑growing segment in vision care.

Intervention/Treatment: The study tests a single device intervention: the A.M.L. series of spectacle lenses. These are myopia control lenses designed for children with nearsightedness. All enrolled children will wear the A.M.L. lenses every day for two weeks, and researchers will track how quickly they get used to the lenses and how comfortable they feel.

Study Design: This is an interventional study with one group only. All 40 children, aged 6 to 12, receive the same A.M.L. lenses, so there is no comparison or placebo group. There is no masking or blinding; both doctors and participants know which lens is used. The main purpose is practical: to measure comfort, adaptation time, and overall satisfaction rather than to test a medical cure or long‑term clinical outcome.

Study Timeline: The trial was first submitted on January 12, 2026, marking the start of formal set‑up and recruitment. Visits are planned at day 4–6, week 1, and week 2 of lens wear to measure early adaptation. The latest update on the record is January 22, 2026, which signals that the protocol and status were recently reviewed. Primary and final completion dates are not yet posted, so investors should expect results later, after enough children finish the two‑week follow‑up.

Market Implications: For EssilorLuxottica, this recruiting study supports its push into myopia control for children, an area with strong long‑term demand as childhood myopia rises worldwide. Positive comfort and adaptation data would strengthen the commercial case for A.M.L. lenses and could support premium pricing, higher volumes, and deeper partnerships with eye‑care professionals. That would be a mild positive for sentiment toward ESLOY, especially for investors focused on structural growth themes in vision care devices. Competitors such as Hoya, Zeiss, and other myopia‑control lens and contact lens makers are also active in this space, so clinical data that highlight ease of use could offer a marketing edge even if the study is small. Until results are disclosed, the direct share price impact is likely limited, but the update confirms ongoing R&D investment and product innovation that support EssilorLuxottica’s long‑term growth story.

The study is currently ongoing and actively updated, with more details available on the ClinicalTrials portal.